Nuvation Bio Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Nuvation Bio Inc. (NUVB) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$2.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-15.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2023-03-15
- Nuvation Bio Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was -$2.00K.
- Nuvation Bio Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2021 was -$1.00K, a 100.01% decline from fiscal 2020.
- Nuvation Bio Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2020 was $12.00M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 8 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 8 month as first filed | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|---|---|
| 2022-12-31 | -$2.00K 10-K · filed 2023-03-15 | ||
| 2021-12-31 | -$1.00K 10-K · filed 2023-03-15 | ||
| 2020-12-31 | $854.74K 10-K/A · filed 2021-05-21 | $911.45 10-K · filed 2021-03-11 | $12.00M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |